Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

The Impact of Multimodal Brain Monitoring on Postoperative Outcomes in Elderly Patients Undergoing Major Abdominal Surgery

15. juli 2026 opdateret af: Xuanwu Hospital, Beijing

Impact of Multimodal Brain Monitoring Under General Anesthesia on Postoperative Outcomes in Elderly Patients Undergoing Major Abdominal Surgery: A Multicenter, Prospective, Single-blind, Randomized Controlled Study

The purpose of this clinical trial is to investigate the effect of multimodal brain monitoring under general anesthesia on postoperative outcomes in elderly patients undergoing abdominal surgery.The research hypothesis is that multimodal brain monitoring under general anesthesia can reduce the incidence of postoperative composite complications and improve postoperative outcomes in elderly patients undergoing major abdominal surgery.

Eligible patients will be randomly assigned in a 1:1 ratio to the Multimodal Brain Monitoring under General Anesthesia Group (MBMGA group) and the Bispectral Index Monitoring under General Anesthesia Group (BIS group). The primary outcome is the postoperative composite complication rate . Secondary outcomes include intraoperative hyperglycemia, adverse events during anesthesia induction and maintanance, changes in blood pressure and heart rate, intraoperative hypotension, the dosage of perioperative anesthetics and vasoactive drugs, changes in serum cortisol, cardiac troponin I, blood creatinine (Cr) level, extubation time and awake time, the rate of transferring to ICU or AICU, The time to first use analgesia pump and the cumulative dose of postoperative oxycodone, systemic complications, hospitalization time, first exhaust time , first oral intake time, rate of second surgery and mortality within 30 days postoperatively.

Participants will:

  1. Undergo routine preoperative fasting for 6-8 hours;
  2. Prior to anesthesia induction, cooperate with the establishment of intravenous access, arterial catheterization, monitoring of physiological parameters, blood sample collection, and receive fluid preloading;
  3. During surgery, for patients in the MBMGA group , propofol and remifentanyl will be adjusted according to multimodal brain monitoring indices (WLi and PTi), while for patients in the BIS group, only propofol will be adjusted based on bispectral index and remifentanyl will be adjusted according to anesthesiologists' experience; simultaneously, vital signs, including respiration, body temperature, fluid therapy, blood pressure, and heart rate regulation, will be monitored and managed.
  4. After surgery, endotracheal tubes will be removed once extubation criteria are met, and patients will be transferred to the PACU, where they will receive routine monitoring and will be discharged from the PACU upon meeting corresponding scoring criteria;
  5. Participates in follow-ups on the day of surgery and for 1-30 days postoperatively, during which investigators will record the primary outcome and secondary outcomes.

Studieoversigt

Status

Ikke rekrutterer endnu

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

368

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

  • Navn: Wei Xiao, Doctor
  • Telefonnummer: 008613810971299
  • E-mail: kitten15@126.com

Studiesteder

    • Beijing Municipality
      • Beijing, Beijing Municipality, Kina
        • Peking University International Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Lan Yao
      • Beijing, Beijing Municipality, Kina, 10053
        • Xuanwu Hospital Capital Medical University
        • Kontakt:
        • Ledende efterforsker:
          • Tianlong Wang
        • Underforsker:
          • Wei Xiao
    • Henan
      • Zhengzhou, Henan, Kina
        • The First Affiliated Hospital of Zhengzhou University
        • Ledende efterforsker:
          • Jianjun Yang
        • Kontakt:
    • Hubei
      • Wuhan, Hubei, Kina
        • Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology
        • Kontakt:
        • Ledende efterforsker:
          • Ailin Luo

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Ældre voksen

Tager imod sunde frivillige

Ingen

Beskrivelse

Inclusion Criteria:

Aged ≥65 years, regardless of gender; Scheduled for elective abdominal surgery with general anesthesia duration (from anesthesia induction to surgery completion) ≥ 2 hours; American Society of Anesthesiologists (ASA) physical status classification of I-III; Body mass index (BMI) of 18.5-29.9 kg/m²; Postoperative hospital stay expected to exceed 72 hours; Compliant with ethical standards, with voluntary signed informed consent.

Exclusion Criteria:

Severe cardiovascular diseases, including:

History of myocardial infarction within the past 6 months; Bradycardia (resting heart rate <50 beats/min); Uncontrolled hypertension (sitting systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg during screening); Sitting systolic blood pressure ≤90 mmHg during screening; History of severe valvular heart disease; Uncontrolled severe respiratory infections: e.g., severe pneumonia, acute bronchitis.

Abnormal liver function: Aspartate Aminotransferase (AST) and/or Alanine Aminotransferase (ALT) ≥2.5×Upper Limit of Normal (ULN), Total Bilirubin (TBIL) ≥1.5×Upper Limit of Normal (ULN); Abnormal renal function: urea or blood urea nitrogen (BUN) ≥1.5×Upper Limit of Normal (ULN), serum creatinine >Upper Limit of Normal (ULN); Admission hemoglobin A1c (HbA1c) ≥6.5% or ≥2 fasting blood glucose measurements ≥180 mg/dl (10 mmol/L) and/or random blood glucose ≥200 mg/dL (≈11.1 mmol/L); Preoperative anemia (Hemoglobin [Hb] ≤90 g/L), thrombocytopenia (Platelet [PLT] ≤80×10⁹/L), hypoproteinemia (Albumin [Alb] ≤30 g/L); History of drug abuse and/or alcoholism within the past 2 years (alcoholism defined as daily average alcohol consumption >2 units, where 1 unit = 360 mL beer or 45 mL 40% ethanol liquor or 150 mL wine); Neurological diseases (e.g., stroke within 6 months, Alzheimer's disease, Parkinson's disease, mental disease, myasthenia gravis) or psychiatric disorders (e.g., schizophrenia, mania, bipolar disorder, delirium), history of long-term use of neuropsychiatric medications, or cognitive impairment; Allergy or contraindication to study medications; Patients refusing or unable to cooperate with the study; Scheduled for pancreatic surgery; Other conditions deemed inappropriate for participation by the investigator.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Forebyggelse
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Dobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Multimodal Brain Monitoring Guided Anesthesia Group(MBMGA Group)
The dosage of propofol is adjusted to maintain WLi in the range of 40-70. While the dosage of remifentanil is adjusted to maintain PTi in the range of 40-70. When intraoperative pain stimulation suddenly increases ( PTi > 70 ) and lead to increased heart rate and elevated blood pressure, remifentanil 0.5-1 μg / kg will be intravenously injected and observed for 1 min. If PTi still is > 70, remifentanil 0.5-1 μg / kg will be added again until PTi reached 40-70.
During the anesthesia induction phase, the dosage administration is guided by the goal of reducing PTi to the range of 40-70, and tracheal intubation is performed when both PTi and WLI are within 40-70. In the anesthesia maintenance phase, the propofol dosage is adjusted according to the WLI value to maintain WLI within 40-70, while the remifentanil dosage is adjusted based on the PTi value to keep PTi within 40-70. In the event of sudden increased intraoperative pain stimulation (PTi > 70) accompanied by tachycardia and hypertension, an intravenous bolus of remifentanil at 0.5-1 μg/kg is administered; after 1 minute of observation, if PTi remains > 70, an additional 0.5-1 μg/kg of remifentanil is given until PTi is brought back to the 40-70 range.
Aktiv komparator: Bispectral Index (BIS) Monitoring Guided Anesthesia Group( BIS Group)
The dosage of propofol is adjusted according to the value of BIS, and the BIS is maintained in the range of 40 ~ 60. The dosage of remifentanil is adjusted according to the experience of anesthesiologists. The intraoperative remifentanil dosage will be maintained between 0.1 μg/kg/min and 0.3μg/kg/min.When it is highly suspected that the sudden increase of pain stimulation during operation leads to the increase of heart rate and blood pressure, remifentanil 0.5 ~ 1 μg / kg will be given intravenously for 1 min. If the heart rate and blood pressure level don't improve, remifentanil 0.5 ~ 1 μg / kg is added again until the heart rate and blood pressure have a downward trend and return to the level before the increase.
During the anesthesia induction phase, the dosage administration is guided by the goal of reducing BIS to the range of 40-60, with remifentanil supplemented based on clinical experience. In the anesthesia maintenance phase, the propofol dosage is adjusted according to BIS values to maintain BIS within 40-60, while the remifentanil dosage is adjusted based on anesthesiologists' experience. When there is a high suspicion of sudden tachycardia and hypertension induced by increased intraoperative pain stimulation, an intravenous bolus of remifentanil at 0.5-1 μg/kg is administered; after 1 minute of observation, if heart rate and blood pressure show no improvement, an additional 0.5-1 μg/kg of remifentanil is given until there is a downward trend in heart rate and blood pressure and they return to pre-stimulation levels.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Incidence of Postoperative Composite Complication
Tidsramme: From post-extubation to postoperative Day 30
The incidence of ≥ 1 complication occurred from the extubation to the 30 th day postoperatively The definition of postoperative composite complications refers to the rate of occurrence of one or more complications from the time of anesthesia extubation to postoperative day 7 (or the day of discharge) and within 30 days after surgery. Postoperative complications are defined as adverse events of Clavien Dindo grade II or higher occurring in any system from postoperative day 1 to day 7 (or the day of discharge) and within 30 days after surgery.
From post-extubation to postoperative Day 30

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Incidence of intraoperative stress-induced hyperglycemia
Tidsramme: From anesthesia induction to skin closure, assessed up to 5 minutes after surgery

Intraoperative stress hyperglycemia is defined as:

A condition diagnosed when a patient meeting all the following criteria:

Preoperative glycemic status:

Two or more fasting blood glucose measurements < 126 mg/dL (≈7.0 mmol/L) or Random blood glucose < 200 mg/dL (≈11.1 mmol/L) during hospitalization, With concurrent HbA1c < 6.5%;

Intraoperative finding:

Highest blood glucose level ≥ 140 mg/dL (≈7.8 mmol/L) when measured at:

1 hour after intubation and/or Upon completion of surgery.

From anesthesia induction to skin closure, assessed up to 5 minutes after surgery
Incidence of intraoperative composite adverse events
Tidsramme: during operation, assessed up to 5 minutes after surgery

Observe and record the incidence of intraoperative composite adverse events .

Adverse events include but are not limited to:

  1. Cardiovascular Complications:

    • Hypotension

      • Hypertension

        • Severe Arrhythmia ④Acute Myocardial Ischemia

          • Acute Myocardial Infarction ⑥Acute Pulmonary Embolism

            • Acute Heart Failure ⑧Deep Vein Thrombosis
  2. Respiratory Complications:

    • Pneumonia

      • Acute Respiratory Distress Syndrome (ARDS)

        • Pulmonary Edema ④Respiratory Failure ⑤Bronchospasm

          ⑥Atelectasis

          ⑦Pleural Effusion

  3. Neurological Complications:

    ①Intraoperative Awareness

    ②Acute Stroke

  4. Renal Complications:

    • Acute Kidney Injury (AKI) ②Acute Renal Failure (ARF)
during operation, assessed up to 5 minutes after surgery
Blood pressure change immediately after intubation
Tidsramme: at anesthesia induction and immediately after intubation, assessed up to 10 seconds after intubation
Record blood pressure before induction and immediately after completion of intubation, and calculate the magnitude of change.
at anesthesia induction and immediately after intubation, assessed up to 10 seconds after intubation
Duration of intraoperative hypotension
Tidsramme: From the anesthesia induction to the end of surgery, assesed up to 5 minutes after surgery

Parameters to be recorded:

Duration of intraoperative hypotension;

Hypotension is defined as:

Mean arterial pressure < 65 mmHg or decrease of mean arterial pressure > 20% from preoperative baseline value.

From the anesthesia induction to the end of surgery, assesed up to 5 minutes after surgery
Total pintraoperative anesthetic/vasoactive drug dosages
Tidsramme: from the anesthesia induction to the end of surgery, assessed up to 5 minutes after surgery

Record the dosages of all medications administered during the intraoperative period, including but not limited to:

General anesthetics: Propofol, Remifentanil, Sufentanil, Oxycodone

Vasoactive agents:

  • Norepinephrine
  • Esmolol
  • Urapidil
  • Atropine
  • Ephedrine
  • Phenylephrine
from the anesthesia induction to the end of surgery, assessed up to 5 minutes after surgery
Serum cortisol levels before surgery and 24 hours postoperatively
Tidsramme: From before surgery and 24 hours post-operation

Measure serum cortisol concentrations at the following time points:

Preoperatively and 24 hours postoperatively

From before surgery and 24 hours post-operation
Durations from drug cessation to awake/extubation
Tidsramme: From drug cessation to awake/extubation , assessed up to 2 hours after entering post-anesthsia care unit
Duration from anesthesia discontinuation to awake and duration from anesthesia discontinuation to extubation
From drug cessation to awake/extubation , assessed up to 2 hours after entering post-anesthsia care unit
Rate of postoperative Intensive Care Unit/Anesthesia Intensive Care Unit transfer
Tidsramme: From the end of surgery to Discharge, assessed up to 2 weeks after surgery
The ratio of postoperative patients requiring transfer to either the Anesthesia Intensive Care Unit or Intensive Care Unit for any clinical indication, to the total number of surgical patients during the same period.
From the end of surgery to Discharge, assessed up to 2 weeks after surgery
Duration to first patient controlled intravenous analgesia pump use
Tidsramme: From the initiation of patient controlled intravenous analgesia pump use to the discontinuation of analgesic pump use, assessed up to 3 days after surgery
The duration from the end of surgery until the first activation of the patient controlled intravenous analgesia pump
From the initiation of patient controlled intravenous analgesia pump use to the discontinuation of analgesic pump use, assessed up to 3 days after surgery
Incidence of complications in other organ systems during the follow-up period except stress induced hyperglycemia
Tidsramme: From the start of surgery to 30 days post-operation

Follow-up assessments will be performed by a single blinded and certified anesthesia practitioner at postoperative days 1-7 and day 30, with documentation of complications involving:

Cardiovascular system; Respiratory system; Digestive system; Nervous system; Urinary system; Infection-related complications,such as wound infection Postoperative complications are defined as adverse events of Clavien Dindo grade II or higher occurring in any system from postoperative day 1 to day 7 (or the day of discharge) and within 30 days after surgery.

From the start of surgery to 30 days post-operation
Length of hospital stay
Tidsramme: From patient admission to discharge, assessed up to 2 weeks after surgery
the duration of patient stay in hospital
From patient admission to discharge, assessed up to 2 weeks after surgery
Rate of second operation
Tidsramme: From immediately after surgery to 30 days postoperatively
Observation and record the rate of secondary surgeries
From immediately after surgery to 30 days postoperatively
Mortality within 30-day postoperatively
Tidsramme: From immediately after surgery to 30 days postoperatively
Record the mortality within 30 days postoperatively.
From immediately after surgery to 30 days postoperatively
Incidence of acute myocardial injury
Tidsramme: From anesthesia induction to 24 hours after surgery
Measure blood cardiac troponin I level at the following time points: Preoperatively and 24 hours postoperatively, measurement of cardiac troponin I exceeds the 99th percentile upper reference limit
From anesthesia induction to 24 hours after surgery
Incidence of acute kidney injury
Tidsramme: From anesthesia induction to 24 hours after surgery

Measure blood creatinine level at the following time points:

1 day before surgery, and 24 hours postoperatively;Acute kidney injury was defined according to the KDIGO criteria as the presence of any of the following: (1) an increase in serum creatinine by ≥26.5 μmol/L (0.3 mg/dL) within 48 hours; (2) an increase in serum creatinine to ≥1.5 times baseline within the previous 7 days; or (3) a urine volume <0.5 mL/kg/h for 6 consecutive hours.

From anesthesia induction to 24 hours after surgery
Incidence of postoperative surgical site infection
Tidsramme: From immediately after surgery to 30 days postoperatively
surgical site infection refers to the proportion of surgical cases with surgical site infection (SSI) occurring from after surgery to before discharge, relative to the total number of surgical procedures performed on hospitalized patients during the same period. Postoperative wound infection is defined as an infection related to the surgical procedure and occurring near the surgical site within 30 days after surgery. Postoperative wound infections include: superficial incisional SSI, deep incisional SSI, and organ/space SSI.
From immediately after surgery to 30 days postoperatively
Heart rate change immediately after intubation
Tidsramme: at anesthesia induction and immediately after intubation, assessed up to 10 seconds after intubation
Record heart rate before induction and immediately after completion of intubation, and calculate the magnitude of change.
at anesthesia induction and immediately after intubation, assessed up to 10 seconds after intubation
Duration to postoperative first flatus time
Tidsramme: From the end of surgery to 7 days after surgery
Duration to postoperative first flatus time
From the end of surgery to 7 days after surgery
Duration to postoperative first oral intake
Tidsramme: From the end of surgery to 7 days after surgery
Duration to postoperative first oral intake
From the end of surgery to 7 days after surgery
Minimum intraoperative mean arterial pressure
Tidsramme: From the anesthesia induction to the end of surgery, assesed up to 5 minutes after surgery

Parameters to be recorded:

Minimum intraoperative mean arterial pressure ;

From the anesthesia induction to the end of surgery, assesed up to 5 minutes after surgery
Incidence of hypotension.
Tidsramme: From the anesthesia induction to the end of surgery, assesed up to 5 minutes after surgery

Parameters to be recorded:

Incidence of hypotension;

Hypotension is defined as:

Mean arterial pressure < 65 mmHg or decrease of mean arterial pressure > 20% from preoperative baseline value.

From the anesthesia induction to the end of surgery, assesed up to 5 minutes after surgery
Durations of post-anesthesia care unit stay
Tidsramme: From entering post-anesthesia care unit to post-anesthesia care unit discharge, assessed up to 2 hours after entering post-anesthsia care unit
Duration of post-anesthesia care unit stay
From entering post-anesthesia care unit to post-anesthesia care unit discharge, assessed up to 2 hours after entering post-anesthsia care unit
Cumulative postoperative oxycodone dosage
Tidsramme: From the initiation of patient controlled intravenous analgesia pump use to the discontinuation of analgesic pump use, assessed up to 3 days after surgery
Cumulative postoperative oxycodone dose
From the initiation of patient controlled intravenous analgesia pump use to the discontinuation of analgesic pump use, assessed up to 3 days after surgery
The duration of intraoperative deep sedation
Tidsramme: from anesthesia induction to the end of surgery, assessed up to 5 minutes after surgery
The duration of intraoperative wavelet index below 40 or Bispectral Index below 40
from anesthesia induction to the end of surgery, assessed up to 5 minutes after surgery
The duration of intraoperative inadequate analgesia
Tidsramme: from anesthesia induction to the end of surgery, assessed up to 5 minutes after surgery
The duration of intraoperative pain threshold index higher than 70
from anesthesia induction to the end of surgery, assessed up to 5 minutes after surgery
Scores of Intake, Feeling nauseated, Emesis, physical Exam, and Duration of symptoms at 72 hours after surgery
Tidsramme: at 72 hours after surgery
Scores of Intake, Feeling nauseated, Emesis, physical Exam, and Duration of symptoms at 72 hours after surgery, Intake, Feeling nauseated, Emesis, physical Exam, and Duration of symptoms is a scoring system to evaluate the postoperative gastrointestinal function, if the score is higher than 6, it indicating gastrointestinal dysfunction.
at 72 hours after surgery

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Efterforskere

  • Ledende efterforsker: Tianlong Wang, Doctor, Xuanwu Hospital, Beijing

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. august 2026

Primær færdiggørelse (Anslået)

30. maj 2028

Studieafslutning (Anslået)

30. december 2028

Datoer for studieregistrering

Først indsendt

13. juli 2026

Først indsendt, der opfyldte QC-kriterier

15. juli 2026

Først opslået (Faktiske)

20. juli 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

20. juli 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

15. juli 2026

Sidst verificeret

1. juli 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • Linyanshen[2025]075-004-xz-1

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-delingstidsramme

One year after results publicated

IPD-delingsadgangskriterier

Contacting the corresponsible author.

IPD-deling Understøttende informationstype

  • STUDY_PROTOCOL

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .